Mesa Laboratories, Inc. Share Price
Stocks
MLAB
US59064R1095
Medical Equipment, Supplies & Distribution
|
Market Closed -
Nasdaq
01:30:00 24/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 133.01 USD | -1.20% |
|
+6.16% | +69.44% |
| 11/08 | Mesa Laboratories, Inc., Q1 2027 Earnings Call, Aug 10, 2026 | |
| 11/08 | Tranche Update on Mesa Laboratories, Inc.'s Equity Buyback Plan announced on November 10, 2005. | CI |
| Market Cap | 74Cr 65Cr 61Cr 56Cr 104.91Cr 7.13TCr 105.69Cr 737.6Cr 285.95Cr 3.64TCr 279.51Cr 273.38Cr 12TCr | P/E 2027 * |
60.3x | P/E 2028 * | 39.8x |
|---|---|---|---|---|---|
| Enterprise Value | 74Cr 65Cr 61Cr 56Cr 104.91Cr 7.13TCr 105.69Cr 737.6Cr 285.95Cr 3.64TCr 279.51Cr 273.38Cr 12TCr | EV / Sales 2027 * |
2.92x | EV / Sales 2028 * | 2.75x |
| Free-Float |
94.38% | Yield 2027 * |
0.48% | Yield 2028 * | 0.48% |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| MLAB | Delayed | |
CBOE
| MLAB | Real-time | |
|
Tradegate
| MLI | Real-time | |
|
Deutsche Boerse AG
| MLI | Delayed | |
|
Boerse Muenchen
| MLI | Real-time |
Last Transcript: Mesa Laboratories, Inc.
| 1 day | -1.20% | ||
| 1 week | +6.16% | ||
| Current month | +4.02% | ||
| 1 month | +6.61% | ||
| 3 months | +44.62% | ||
| 6 months | +61.42% | ||
| Current year | +69.44% |
| 1 week | 124.5 |  | 136.31 |
| 1 month | 119.07 | | 136.31 |
| Current year | 71.06 | | 136.31 |
| 1 year | 63.48 | | 136.31 |
| 3 years | 55.45 | | 155.12 |
| 5 years | 55.45 | | 333.42 |
| 10 years | 55.45 | | 333.42 |
| Manager | Title | Age | Since |
|---|---|---|---|
Siddhartha Kadia
CEO | Chief Executive Officer | 57 | 12/04/2026 |
John Sakys
DFI | Director of Finance/CFO | 58 | 29/10/2012 |
Lyndsey Crennen
AUD | Comptroller/Controller/Auditor | 41 | 01/01/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
John Sullivan
CHM | Chairman | 73 | 01/09/2017 |
Jennifer Alltoft
BRD | Director/Board Member | 58 | 04/03/2019 |
Shannon Hall
BRD | Director/Board Member | 57 | 11/05/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 09/09/26 | Free | Director | 2,510 | 0.0449% | ||
| 09/09/26 | Free | Director | 2,423 | 0.0433% | ||
| 09/09/26 | Free | Director | 1,774 | 0.0317% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.20% | +6.16% | +89.64% | +17.77% | 74Cr | |
| -0.19% | +1.10% | -23.84% | +5.44% | 18TCr | |
| -1.62% | -3.56% | -5.96% | +11.25% | 11TCr | |
| -0.68% | -1.95% | +3.27% | +67.94% | 5.96TCr | |
| -0.26% | +0.37% | -2.14% | -31.18% | 4.97TCr | |
| +2.37% | +2.14% | +10.45% | +50.06% | 4.78TCr | |
| -2.01% | +0.45% | +28.64% | +0.26% | 3.31TCr | |
| -0.38% | +3.97% | - | - | 3.01TCr | |
| +1.29% | +3.83% | +49.87% | +0.90% | 2.65TCr | |
| +0.19% | +5.05% | +13.62% | -9.17% | 2.28TCr | |
| Average | -0.39% | +1.58% | +18.17% | +12.59% | 5.64TCr | |
| Weighted average by Cap. | -0.81% | +0.09% | -3.22% | +13.09% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 26Cr 22Cr 21Cr 19Cr 36Cr 2.45TCr 36Cr 253Cr 98Cr 1.25TCr 96Cr 94Cr 4.04TCr | 27Cr 24Cr 22Cr 20Cr 38Cr 2.59TCr 38Cr 267.83Cr 103.83Cr 1.32TCr 101.49Cr 99Cr 4.28TCr |
| Net income | 1.33Cr 1.16Cr 1.09Cr 1Cr 1.87Cr 127.08Cr 1.88Cr 13Cr 5.1Cr 65Cr 4.98Cr 4.87Cr 210.07Cr | 2.11Cr 1.85Cr 1.74Cr 1.59Cr 2.98Cr 202.44Cr 3Cr 21Cr 8.12Cr 103.21Cr 7.94Cr 7.76Cr 334.64Cr |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/26/23 | $133.01 | -1.20% | 1,05,452 |
| 22/26/22 | $134.63 | +2.09% | 1,14,660 |
| 21/26/21 | $131.87 | +4.21% | 1,14,134 |
| 18/26/18 | $126.54 | -0.47% | 1,36,666 |
| 17/26/17 | $127.14 | +1.48% | 72,172 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MLAB Stock
Select your edition
All financial news and data tailored to specific country editions
